11|06|26

Rare Diseases Are Not a Niche: Rethinking Opportunity in Europe

Rare diseases present a unique opportunity to rethink how innovation, evidence, and access come together across Europe. In a new Q&A with pharmaphorum, Alberta Spreafico, SVP, Health Innovation at EVERSANA, explores the evolving rare disease landscape and what it means for organizations working to bring meaningful innovation to patients. Read the full Q&A to hear […]

11|06|26

ChatGPT Ads: October 2026 Update and Implications

The advertising landscape in generative AI is moving quickly, and pharma marketers should be paying attention. Since ChatGPT Ads launched in February 2026, OpenAI has rapidly expanded the program to more than 60 countries. While branded prescription drug promotion remains prohibited, recent policy changes have introduced a case-by-case review pathway for select U.S. health categories, including unbranded disease awareness.

10|21|26

Rethinking Commercial Pharma in the Age of AI

Where is AI creating meaningful value in commercial pharma today, and where are expectations still ahead of reality? That question was at the center of Where AI is (and isn't) Changing Commercial Work, the second installment of MATTER's AI in Commercial Pharma series. Faruk Capan, Founder of our agency and Chief Innovation Officer at EVERSANA, joined leaders from Sanofi and Lundbeck to explore how organizations are approaching AI, the challenges impacting adoption and how commercial models could evolve in the years ahead.

10|02|26

Back-to-Back Silver Market Access Agency of the Year Recognition

We’re proud to share that EVERSANA INTOUCH Market Access was honored as Silver Market Access Agency of the Year for the second consecutive year! This recognition solidifies our position as a leader in our industry and highlights our commitment to guiding our clients through the complexities of market access with precision, purpose, and impact.

09|23|26

From Direct-to-Patient to Direct-to-Disease: A New Commercialization Model for Europe

As digital-first healthcare pathways continue to evolve across Europe, pharmaceutical companies face a critical question: how can they responsibly support patient access while navigating complex regulatory environments and changing patient expectations? Our latest POV, explores the rise of Direct-to-Disease (DTD) models and how digital ecosystems are reshaping the way patients discover, access, and engage with care.

09|17|26

Beyond the Data: Why Scientific Storytelling Matters More Than Ever

In today’s healthcare landscape, generating evidence is only part of the challenge. As healthcare professionals navigate an ever-increasing volume of scientific information, the ability to transform complex data into meaningful, memorable narratives has become critical. In this POV, Harriet Painter, VP of Medical Communications, explores how scientific storytelling can help Medical Affairs teams improve understanding, strengthen engagement, and support better clinical decision-making.

09|09|26

AI Is Reshaping How Patients Find Health Information

A new article from World of DTC Marketing highlights findings from our 2026 Pharma AI Overviews Report, revealing how AI is rapidly becoming patients' first stop for health information and reshaping the traditional path to pharma and healthcare websites. Read the blog to explore what this shift means for marketers and how brands can stay ahead as search behavior evolves.

09|02|26

Beyond AI-Enabled: Why a New Partner Model Is Vital for Pharmaceutical Marketing in Europe

European pharmaceutical marketers are navigating a uniquely complex landscape, balancing diverse healthcare systems, regulatory environments and market-specific needs. As AI continues to transform commercialization, the conversation must move beyond efficiency gains and automation toward a more fundamental question: what should the future client-agency partnership look like? In this POV, Michael Le Brocq, Global Head of […]

08|31|26

Beyond the Single Click-Out: Snapchat Opens the Door to Branded Rx

For years, pharmaceutical marketers have faced a challenge on Snapchat: balancing engaging branded content with the disclosure requirements necessary for compliant Rx advertising. That may be changing. In a new POV, Ali Hudson, Media Director, Paid Social, and Juniper Valeo, Director, Social Media, explore Snapchat’s newly announced multi-CTA attachments product, which allows brands to pair […]

08|06|26

What ChatGPT Ads Mean for Pharma Search

Explore the critical differences between ChatGPT Ads and standard search, the unique regulatory challenges ahead, and the exact steps pharma brands must take now to prepare for inevitable platform access.